Faster Targeted Therapy

Earlier detection of ‘bad actor’ organisms with T2Direct Diagnostics

Speed is critical in sepsis management: the faster patients receive effective treatment, the more likely they are to survive. Early detection and identification of clinically important organisms frequently missed by initial empiric therapy, provides an opportunity for earlier targeted therapy.

Early Targeted Therapy Starts in the Lab

Clinicians typically wait 1 to 5 or more days for species identification results based on blood culture. Now with T2Direct Diagnostics, labs can provide rapid species identification to inform therapy decisions within hours of blood draw, without waiting for a blood culture result.

  • In a study published in The Journal of Antimicrobial Stewardship, the Henry Ford Health System tested patients with T2Direct Diagnostics and found they were treated in a median of 5 hours – more than 8x faster compared to blood culture. Waiting for blood culture delayed appropriate therapy by a median of 44 hours.3
  • Lee Health System reduced the average time to appropriate antifungal therapy by 34 hours. Previously, time to appropriate therapy averaged 40 hours; with the T2Candida Panel, investigators reported an average of 6 hours.4

“This technology has shown it can expedite the detection of candidemia. As a result, patients receive more prompt and appropriate antifungal therapy.”
 

Rachel Kenney, PharmD, Henry Ford study co-author.

Download the study on faster targeted treatment at Henry Ford Hospital.

Get T2Direct Diagnostics! Request a meeting.

……………………………………….
1. Buehler S.S., Madison B., Snyder S.R., et al. 2016. Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. Clinicanl microbiology review, 29:59–103. doi:10.1128/CMR.00053-14.
2. Kumar, A., Roberts, D., Wood, K. E., et al. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6), 1589-1596.
3. Wilson, N.M., Alangaden, G., Tibbetts, R.J., et al. (2017). T2 Magnetic Resonance assay improves timely management of candidemia. Journal of antimicrobial stewardship, 1, 12-18.
4. Estrada, S. J. Real world value of T2Candida, Lee Memorial Hospital. Slide Presentation ASM 2016.